Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H18N2O3 |
Molecular Weight | 310.3471 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CCC(O)=O)C(C)=C(N1)\C=C2/C(=O)NC3=C2C=CC=C3
InChI
InChIKey=NHFDRBXTEDBWCZ-ZROIWOOFSA-N
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
Molecular Formula | C18H18N2O3 |
Molecular Weight | 310.3471 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Orantinib (SU-6668) is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Orantinib was in phase II clinical trials for the treatment of breast cancer. It was also in phase III clinical trials for the treatment of hepatocellular carcinoma. However, this research was terminated in 2014. The compound was originally developed by Sugen (subsidiary of Pfizer). In 1998, a co-development agreement took place between Sugen and Taiho for the compound.
Originator
Sources: http://adisinsight.springer.com/drugs/800011006
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1913 |
0.06 µM [IC50] | ||
Target ID: CHEMBL279 |
2.43 µM [IC50] | ||
Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10602697 |
3.04 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Combined antiangiogenic and immune therapy of prostate cancer. | 2005 |
|
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. | 2005 Feb |
|
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. | 2005 Sep 1 |
|
Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives. | 2007 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28988687
Orantinib at 200 mg, twice per day, or placebo was given orally until TACE failure or unacceptable toxicity.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10945623
Orantinib (SU-6668) inhibited PDGF-stimulated PDGFRb tyrosine phosphorylation in NIH-3T3 cells overexpressing PDGFRb at a minimum concentration of 0.03–0.1 uM. SU-6668 inhibited acidic FGF-induced
phosphorylation of the FGFR1 substrate 2 (FRS-2) at concentrations
of 10 uM and higher. However, SU-6668 had no detectable
effect on epidermal growth factor-stimulated EGFR tyrosine phosphorylation
in NIH-3T3 cells overexpressing EGFR at concentrations of up to 100 uM. Orantinib (SU-6668) inhibited VEGF-driven mitogenesis of HUVECs in a dose-dependent
manner with a mean IC50 of 0.34 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:37:19 GMT 2023
by
admin
on
Fri Dec 15 16:37:19 GMT 2023
|
Record UNII |
9RL37ZZ665
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5329099
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL274654
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
252916-29-3
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
SUB74858
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
702827
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
PRIMARY | |||
|
91088
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
DTXSID5043716
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
C412603
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
PRIMARY | |||
|
C1884
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
PRIMARY | |||
|
DB12072
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
9267
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
9RL37ZZ665
Created by
admin on Fri Dec 15 16:37:19 GMT 2023 , Edited by admin on Fri Dec 15 16:37:19 GMT 2023
|
PRIMARY | |||
|
100000136798
Created by
admin on Fri Dec 15 16:37:20 GMT 2023 , Edited by admin on Fri Dec 15 16:37:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INDUCER |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |